Re­Vi­ral taps Seth Het­her­ing­ton to guide up­com­ing PhI­Ia; In­cyte, Aquinox ex­ecs move to AI shop No­table Labs

→ Ox­ford, Eng­land-based vac­cine de­vel­op­er Emergex has re­cruit­ed Big Phar­ma vet Athana­sios Pa­padopou­los to be its CMO. Jump­ing from Sanofi — where he helped de­vel­op the ground­break­ing but ill-fat­ed Deng­vax­ia — Pa­padopou­los in­her­its a uni­ver­sal Fla­vivirus vac­cine can­di­date now poised for Phase I in H2 2019 and a new R&D fa­cil­i­ty for Emergex’s syn­thet­ic vac­cines.

Re­Vi­ral has tapped Seth Het­her­ing­ton to steer its lead RSV can­di­date in­to pe­di­atric Phase IIa tri­als. As CMO (a role he re­cent­ly held for sev­en years at Geno­cea Bio­sciences), Het­her­ing­ton will lead the biotech in nav­i­gat­ing a field full of nasty sur­pris­es, though Re­Vi­ral has rea­sons to be con­fi­dent giv­en pos­i­tive re­sults in a pre­vi­ous PhI­Ia. He will be based in the British com­pa­ny’s US of­fice.

→ On a quest to prove its au­to­mat­ed lab­o­ra­to­ry can lead to faster, cheap­er de­vel­op­ment of drugs, AI start­up No­table Labs has re­cruit­ed two in­dus­try vets to steer the can­cer drug pro­gram it’s just launched. Hi­roo­mi Ta­da, a re­cent In­cyte ex­ec and Glax­o­SmithK­line alum, comes on as chief med­ical of­fi­cer while Lloyd Macken­zie will as­sume the ti­tle chief de­vel­op­ment of­fi­cer af­ter run­ning R&D at Aquinox for 11 years.

Atre­ca has brought in Herb Cross to re­place re­tir­ing CFO Su­san Berland, who will re­main a con­sul­tant to the com­pa­ny. This will be Cross’ fifth time in the role, hav­ing re­cent­ly led Ar­mo Bio­sciences through an IPO and ul­ti­mate­ly a sale to Eli Lil­ly

→ Af­ter spend­ing six years scout­ing col­lab­o­ra­tions for PCI Biotech’s pho­to­chem­i­cal in­ter­nal­iza­tion tech plat­form for can­cer, Gaël L’Hévéder is mov­ing on­to a new stint. His res­ig­na­tion will be ef­fec­tive at the end of the month. A sea­soned BD ex­ec, L’Hévéder’s re­sume fea­tures stints at Roche and Sanofi as well as a short time run­ning his own start­up in Switzer­land.

→ Two years af­ter bring­ing out the bud­get ax and shak­ing up its glob­al R&D group, Dai­ichi Sankyo is re­vamp­ing the lead­er­ship of its re­search arm and shift­ing the cen­ter of grav­i­ty to the US. Who’s out: Glenn Gorm­ley, who took the R&D reins at Dai­ichi Sankyo in 2011 af­ter a 20-year run at three big phar­ma groups: Mer­ck, As­traZeneca and No­var­tis. He’ll stay on, though, as chair­man of the board and spe­cial ad­vis­er to glob­al CEO Jo­ji Nakaya­ma. Who’s in: Ju­nichi Ko­ga, who’s get­ting a pro­mo­tion from head of the R&D group in Japan to the over­all chief’s po­si­tion, based in New Jer­sey.

→ Fol­low­ing a rough few weeks, the re­volv­ing door at the ex­ec­u­tive suite to Im­munomedics $IM­MU is turn­ing once more. CEO Michael Pehl has de­cid­ed to leave for per­son­al rea­sons. His abrupt ex­it af­ter 15 months on the job comes a lit­tle more than a month af­ter the FDA hand­ed the com­pa­ny a CRL for its ap­pli­ca­tion to mar­ket the an­ti­body drug con­ju­gate IM­MU-132, or sac­i­tuzum­ab govite­can. Pehl was brought in to end the long-run­ning dra­ma over the drug and the com­pa­ny, which had been tak­en over by the crew led by ven­Bio’s Be­hzad Ag­haz­adeh.

Amy Mc­K­ee, one of Richard Paz­dur’s close al­lies in build­ing out the On­col­o­gy Cen­ter of Ex­cel­lence at the FDA, has left the agency to be­come VP of reg­u­la­to­ry con­sult­ing ser­vices at Parex­el. At the CRO, she joins a nascent on­col­o­gy ini­tia­tive ded­i­cat­ed to con­nect­ing dif­fer­ent busi­ness units to work up de­vel­op­ment plans, guid­ing com­pa­nies in nav­i­gat­ing a reg­u­la­to­ry land­scape she helped shape.

→ Mit­subishi Tan­abe’s US unit has el­e­vat­ed Sam Shum to its lead­er­ship team as VP of op­er­a­tions and strat­e­gy, trust­ing him with every­thing from fi­nance, busi­ness process and pub­lic af­fairs to sup­ply chain and qual­i­ty as­sur­ance. That marks a sig­nif­i­cant ex­pan­sion in re­spon­si­bil­i­ties from Shum’s pre­vi­ous role as se­nior di­rec­tor of fi­nanc­ing plan­ning and an­a­lyt­ics. He fills the shoes of Ar­mand Famigli­et­ti, who is be­com­ing an ad­vis­er to the com­pa­ny.

Todd Wood is the new chief com­mer­cial of­fi­cer at DermTech, tasked with lin­ing up re­im­burse­ments for its pre­ci­sion di­ag­nos­tic prod­ucts for skin can­cers, in­flam­ma­to­ry dis­eases and oth­er der­ma­to­log­i­cal in­di­ca­tions.

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

President Donald Trump (left) and Moncef Slaoui, head of Operation Warp Speed (Alex Brandon, AP Images)

UP­DAT­ED: White House names fi­nal­ists for Op­er­a­tion Warp Speed — with 5 ex­pect­ed names and one no­table omis­sion

A month after word first broke of the Trump Administration’s plan to rapidly accelerate the development and production of a Covid-19 vaccine, the White House has selected the five vaccine candidates they consider most likely to succeed, The New York Times reported.

Most of the names in the plan, known as Operation Warp Speed, will come as little surprise to those who have watched the last four months of vaccine developments: Moderna, which was the first vaccine to reach humans and is now the furthest along of any US effort; J&J, which has not gone into trials but received around $500 million in funding from BARDA earlier this year; the joint AstraZeneca-Oxford venture which was granted $1.2 billion from BARDA two weeks ago; Pfizer, which has been working with the mRNA biotech BioNTech; and Merck, which just entered the race and expects to put their two vaccine candidates into humans later this year.

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Leen Kawas, Athira CEO (Athira)

Can a small biotech suc­cess­ful­ly tack­le an Ever­est climb like Alzheimer’s? Athi­ra has $85M and some in­flu­en­tial back­ers ready to give it a shot

There haven’t been a lot of big venture rounds for biotech companies looking to run a Phase II study in Alzheimer’s.

The field has been a disaster over the past decade. Amyloid didn’t pan out as a target — going down in a litany of Phase III failures — and is now making its last stand at Biogen. Tau is a comer, but when you look around and all you see is destruction, the idea of backing a startup trying to find complex cocktails to swing the course of this devilishly complicated memory-wasting disease would daunt the pluckiest investors.

GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How long will the mo­nop­oly last?

In 2011, GlaxoSmithKline’s Benlysta became the first biologic to win approval for lupus patients. Nine years on, the British drugmaker has unveiled detailed positive results from a study testing the drug in lupus patients with associated kidney disease — a post-marketing requirement from the initial FDA approval.

Lupus is a drug developer’s nightmare. In the last six decades, there has been just one FDA approval (Benlysta), with the field resembling a graveyard in recent years with a string of failures including UCB and Biogen’s late-stage flop, as well as defeats in Xencor and Sanofi’s programs. One of the main reasons the success has eluded researchers is because lupus, akin to cancer, is not just one disease — it really is a disease of many diseases, noted Al Roy, executive director of Lupus Clinical Investigators Network, an initiative of New York-based Lupus Research Alliance that claims it is the world’s leading private funder of lupus research, in an interview.

Covid-19 roundup: Mod­er­na read­ies to en­ter PhI­II in Ju­ly, As­traZeneca not far be­hind; EU ready to ne­go­ti­ate vac­cine ac­cess with $2.7B fund

Moderna may soon add another first to the Covid-19 vaccine race.

In March, the mRNA biotech was the first company to put a Covid-19 vaccine into humans. Next month, they may become the first company to put their vaccine into the large, late-stage trials that are needed to prove whether the vaccine is effective.

In an interview with JAMA editor Howard Bauchner, NIAID chief Anthony Fauci said that a 30,000-person, Phase III trial for Moderna’s vaccine could start in July. The news comes a week after Moderna began a Phase II study that will enroll several hundred people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.

José Basel­ga finds promise in new class of RNA-mod­i­fy­ing can­cer tar­gets, lock­ing in 3 pre­clin­i­cal pro­grams with $55M

Having dived early into some of the RNA breakthroughs of the last decades — betting on Moderna’s mRNA tech and teaming up with Silence on the siRNA front — AstraZeneca is jumping into a new arena: going after proteins that modify RNA.

Their partner of choice is Accent Therapeutics, which is receiving $55 million in upfront payment to steer a selected preclinical program through to the end of Phase I. After AstraZeneca takes over, the Lexington, MA-based startup has the option to co-develop and co-commercialize in the US — and collect up to $1.1 billion in milestones in the long run. The deal also covers two other potential drug candidates.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.

Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

Caught in a stand­off with its con­tract man­u­fac­tur­er over Covid-19 vac­cine, In­ovio files suit in an at­tempt to break free while ri­vals race ahead

Inovio was one of the first vaccine developers to snag attention for a jab that their execs said promised to end the Covid-19 pandemic. Using their own unique DNA tech, CEO Joseph Kim said it took just 3 hours to work it out.

But while rivals are racing to the finish line with ambitious plans to make vast quantities of their vaccines with billions of dollars of deals, Inovio is still stuck at the starting line on manufacturing.